The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial

Journal of the American College of Cardiology

Volumn 43, Issue 7, 2004, Pages 1211-1216

  Pratt, Craig M ^a   Singh, Steven N ^b   Al Khalidi, Hussein R ^c   Brum, Jose M ^c   Holroyde, Michael J ^c   Marcello, Stephen R ^c   Schwartz, Peter J ^d   Camm, A John ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d UNIVERSITY OF PAVIA   (Italy)

^e ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

AF; ALIVE; Atrial fibrillation; AZ; Azimilide dihydrochloride; Azimilide Postinfarct Survival Evaluation; CHF STAT; CI; Confidence interval; DIAMOND; Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

Indexed keywords

ACETYLSALICYLIC ACID; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE CONTRACTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MORTALITY; PATIENT MONITORING; PATIENT SELECTION; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; STATISTICAL SIGNIFICANCE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE, CONGESTIVE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; IMIDAZOLIDINES; MALE; MIDDLE AGED; NEUTROPENIA; PIPERAZINES; PREVALENCE; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 1842582818     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.10.057     Document Type: Article

References (18)

1. Benjamin E.J., Ley D., Vaziri S.M., et al. Independent risk factors for atrial fibrillation in a population-based cohort The Framingham Heart study. JAMA. 271:1994;840-844.
2. Benjamin E.J., Wolf P.A., D'Agostino R.B., et al. Impact of atrial fibrillation on the risk of death The Framingham Heart study. Circulation. 98:1998;946-952.
3. Vaziri S.M., Larson M.G., Benjamin E.J. Echocardiographic predictors of nonrheumatic atrial fibrillation The Framingham Heart study. Circulation. 89:1994;724-730.
4. Prystowsky E.N., Benson D.W. Jr, Fuster V., et al. Management of patients with atrial fibrillation A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 93:1996;1277.
5. Pritchett E.L.C., Page R.L., Connolly S.J., et al. Antiarrhythmic effects of azimilide in atrial fibrillation Efficacy and dose-response. J Am Coll Cardiol. 36:2000;794-802.
6. Singer I, Al-Khalidi H, Niazi I, et al. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with ICDs. J Am Coll Cardiol. In Press.
7. Connolly S.J., Schnell D.J., Page R.L., et al. Dose-response relations of azimilide in the management of symptomatic recurrent, atrial fibrillation. Am J Cardiol. 88:2001;974-979.
8. Slavik R.S., Tisdale J.E., Borzak S. Pharmacologic conversion of atrial fibrillation A systematic review of available evidence. Prog Cardiovasc Dis. 44:2003;121-152.
9. Camm A.J., Karam R., Pratt C. The Azimilide Post-Infarction Survival Evaluation (ALIVE) trial. Am J Cardiol. 81:1998;35D-39D.
10. Collett D. Modelling Survival Data in Medical Research. 1994;Chapman & Hall, London.
11. Davis C.S. Statistical Methods for the Analysis of Repeated Measurements. 2002;Springer-Verlag, New York, NY.
12. Køber L., Bloch-Thomsen P.E., Møller M., et al. Danish Investigators of Arrhythmia and Mortality on Dofetilide (DIAMOND) Study Group. Effect of dofetilide in patients with recent myocardial infarction and left ventricular dysfunction Results of the DIAMOND-MI study. Lancet. 356:2000;2052-2058.
13. Pedersen O.D., Bagger H., Keller N., et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function A DIAMOND substudy. Circulation. 104:2001;292-296.
14. Torp-Pedersen C., Møller M., Bloch-Thomsen P.E., et al. Effect of dofetilide on mortality and morbidity in congestive heart failure and left ventricular function The DIAMOND-CHF study. N Engl J Med. 341:1999;857-865.
15. Naccarelli G.V., Wolbrette D.L., Patel H.M., et al. Amoidaron Clinical trials. Curr Opin Cardiol. 15:2000;64-72.
16. Singh S.N., Fletcher R.D., Fisher S.G., et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (CHF-STAT). N Engl J Med. 333:1995;77-82.
17. Fuster V., Ryden L.E., Asinger R.W., et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Circulation. 104:2001;2118-2150.
18. Khairy P., Nattel S. New insights into the mechanisms and management of atrial fibrillation. CMAJ. 167:2002;1012-1020.